Filtered By:
Source: Journal of Thrombosis and Thrombolysis
Condition: Thrombosis

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 309 results found since Jan 2013.

Thromboembolic complications in inflammatory bowel disease
Abstract Patients with inflammatory bowel disease (IBD) have a 1.5–3.5-fold higher risk of thromboembolism when compared to the non-IBD population and the risk is much more prominent at the time of a flare. Arterial thromboembolism (ischemic stroke, focal white matter ischemia, cardiac ischemia, peripheral vascular disease and mesenteric ischemia) and venous thromboembolism (deep vein thrombosis and pulmonary embolism, cerebral venous sinus thrombosis, retinal, hepatic, portal and mesenteric vein thromboses) belong to the group of underestimated extraintestinal complications in IBD patients, which are associate...
Source: Journal of Thrombosis and Thrombolysis - March 31, 2015 Category: Hematology Source Type: research

Current antiplatelet agents: place in therapy and role of genetic testing
Abstract Antiplatelet therapies play a central role in reducing the risk of cardiovascular events such as myocardial infarction and stroke. While aspirin, a cyclo-oxygenase-1 inhibitor has been the cornerstone of antithrombotic treatment for several decades, P2Y12 receptor inhibitors cangrelor, clopidogrel, prasugrel, and ticagrelor and protease-activated receptor-1 antagonist vorapaxar, have emerged as additional therapies to reduce the risk of recurrent cardiovascular events in high-risk patients. Recent clinical trials evaluating the role of these agents and major society guideline updates for use of antiplatel...
Source: Journal of Thrombosis and Thrombolysis - February 21, 2015 Category: Hematology Source Type: research

Anticoagulation therapy in 2015: where we are and where we are going
Abstract Oral anticoagulants are a mainstay for the prevention and treatment of venous and arterial thrombosis. In 2015, the non-vitamin K oral anticoagulants (NOACs) are already replacing warfarin for many indications. Ongoing studies are focused on development of antidotes and specific reversal agents for the NOACs, and assessing their utility for prevention of cardiovascular events in patients with heart failure, coronary or peripheral artery disease, or embolic stroke of unknown source. This paper (a) lists the current indications for the NOACs; (b) reviews the current impact of the NOACs in each of these indi...
Source: Journal of Thrombosis and Thrombolysis - February 19, 2015 Category: Hematology Source Type: research

Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review
Abstract Edoxaban, an oral direct inhibitor of factor Xa, was recently approved in the United States and Japan for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for treatment of venous thromboembolism (VTE). It is also licensed in Japan for prevention of VTE after major orthopedic surgery. Although routine laboratory monitoring of edoxaban is not required, laboratory measurement may be desirable in special circumstances. Our objective was to provide a systematic review of current evidence on laboratory measurement of the anticoagulant activity of edoxaban. PubMed ...
Source: Journal of Thrombosis and Thrombolysis - February 11, 2015 Category: Hematology Source Type: research

Patient-reported health preferences of anticoagulant-related outcomes
This study aimed to use direct measures to elicit patient-reported utilities (i.e., preferences) for anticoagulant-related outcomes. A cross-sectional survey was administered to 100 patients taking warfarin in an anticoagulation clinic. Utilities for six long-term and four short-term anticoagulant-related health states were elicited by the visual analogue scale (VAS) and standard gamble (SG) methods. Health states with the highest SG-derived mean utility values were “well on rivaroxaban” (mean ± SD = 0.90 ± 0.15), “well on warfarin” (0.86 ± 0.17), and “well on dabigatran” (0.83 ± 0.18). Approximat...
Source: Journal of Thrombosis and Thrombolysis - February 11, 2015 Category: Hematology Source Type: research

New approaches to managing nonvalvular atrial fibrillation: what are the thromboembolic implications?
Abstract This review addresses current treatment strategies for nonvalvular atrial fibrillation (AF) and their potential impact on thromboembolic risk and complications. It updates current classification schemes for the arrhythmia and discusses specific treatment alternatives including rate control, pharmacologic rhythm suppression, catheter ablation, and left atrial appendage obliteration, each in context of thromboembolic risks and stroke prevention.
Source: Journal of Thrombosis and Thrombolysis - February 4, 2015 Category: Hematology Source Type: research

Is plasma C3 and C4 levels useful in young cerebral ischemic stroke patients? Associations with prognosis at 3 months
Abstract Plasma complement C3 and C4 act as risk factor for vascular diseases related to atherosclerosis. The association C3 and C4 levels in young ischemic stroke patients with the prognosis were still not unknown. We conducted this study to establish the significance of admission C3 and C4 levels as a possible predictor of 3 months prognosis in young patients with acute ischemic stroke. We conducted this study in 1,451 young Chinese patients as determined by the modified Rankin Scale at 3 months. Bivariate logistic regression analyses were used to determine the risk factors of outcome in male and female patie...
Source: Journal of Thrombosis and Thrombolysis - February 1, 2015 Category: Hematology Source Type: research

Survival analysis in patients with ischemic stroke
Source: Journal of Thrombosis and Thrombolysis - January 23, 2015 Category: Hematology Source Type: research

Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment
Abstract Target specific anticoagulants (TSOACs) have recently been introduced to the US market for multiple indications including venous thromboembolism (VTE) prevention in total hip and knee replacement surgeries, VTE treatment and reduction in the risk of stroke in patients with non-valvular atrial fibrillation (NVAF). Currently, three TSOACs are available including rivaroxaban, apixaban, and dabigatran with edoxaban currently under Food and Drug Administration review for VTE treatment and stroke prevention in NVAF. The introduction of these agents has created a paradigm shift in anticoagulation by considerably...
Source: Journal of Thrombosis and Thrombolysis - January 21, 2015 Category: Hematology Source Type: research

Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials
Abstract The aim of this study was to obtain best estimates of the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAPT: aspirin, clopidogrel and cilostazol) compared with dual antiplatelet therapy (DAPT: aspirin and clopidogrel) in patients undergoing coronary stent implantation. We searched the literature to identify all randomized clinical trials examining efficacy and safety of TAPT versus DAPT in patients undergoing coronary stent implantation. Major efficacy outcomes were death, non-fatal myocardial infarction (MI), ischemic stroke and stent thrombosis (ST) and the safety outcome was bl...
Source: Journal of Thrombosis and Thrombolysis - January 1, 2015 Category: Hematology Source Type: research

Management of anticoagulation and antiplatelet therapy in patients with left ventricular assist devices
Abstract Left ventricular assist devices (LVADs) have increased the survival of patients with advanced heart failure fourfold. Despite these advances, significant bleeding and thrombotic complications occur. Hemorrhage requiring surgery has been reported in up to 30 % of adults and 50 % of children after LVAD placement. LVAD thrombosis and embolic stroke lead to significant long-term morbidity. Adults are treated with antithrombotic therapy to prevent thrombotic complications, but the amount and intensity of treatment differs between institutions. The goal international normalized ratio for warfarin therapy vari...
Source: Journal of Thrombosis and Thrombolysis - December 31, 2014 Category: Hematology Source Type: research

Novel oral anticoagulants in patients undergoing cardioversion for atrial fibrillation
Abstract Recent trials on novel oral anticoagulants (NOAC) in patients undergoing cardioversion showed that NOACs are as safe and effective as treatment with vitamin K antagonists in patients with atrial fibrillation undergoing electric or pharmacological cardioversion. We conducted an EMBASE and MEDLINE search for studies in which patients undergoing cardioversion were assigned to treatment with NOACs versus VKAs. We identified one prospective randomized study and three post hoc analysis of randomized trials which enrolled 2,788 controls that received NOACs and 1,729 patients that received VKAs. NOACs and VKA...
Source: Journal of Thrombosis and Thrombolysis - December 27, 2014 Category: Hematology Source Type: research

Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation
Abstract While the use of warfarin has been the cornerstone of thromboembolism prevention in patients with atrial fibrillation (AF), its limitations have led to the introduction of a new generation of direct-acting oral anticoagulants. Evidence from large phase III clinical trials, observational studies and pharmacokinetic analyses can guide clinicians to select the most effective and safest form of anticoagulation for patients with nonvalvular AF. This manuscript describes the main pharmacologic, clinical and epidemiological characteristics of each new oral anticoagulant and their use in selected clinical scenari...
Source: Journal of Thrombosis and Thrombolysis - November 22, 2014 Category: Hematology Source Type: research

Ischemic stroke associated with immune thrombocytopenia
The objective of this study was to review all cases in literature in which the clinical manifestations of ischemic stroke and immune thrombocytopenia (ITP) were presented in the same patient including a new case of our own and discuss the possible mechanism and management of this syndrome. We reviewed 12 reports in which 18 cases were diagnosed as ischemic stroke and ITP. The clinical manifestations and ischemic lesion patterns of the 18 cases and our new case were analyzed in detail to elucidate the characteristics and management of this kind of syndrome. Of all the cases, 8 females and 10 males, 10 of them were Koreans; ...
Source: Journal of Thrombosis and Thrombolysis - November 8, 2014 Category: Hematology Source Type: research

Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States
Abstract This retrospective analysis investigated the impact of baseline clinical characteristics, including atrial fibrillation (AF), on hospital discharge status (to home or continuing care), mortality, length of hospital stay, and treatment costs in patients hospitalized for stroke. The analysis included adult patients hospitalized with a primary diagnosis of ischemic or hemorrhagic stroke between January 2006 and June 2011 from the premier alliance database, a large nationally representative database of inpatient health records. Patients included in the analysis were categorized as with or without AF, based on...
Source: Journal of Thrombosis and Thrombolysis - November 5, 2014 Category: Hematology Source Type: research